(MTX) MTU Aero Engines - Ratings and Ratios
Commercial Engines, Military Engines, Gas Turbines, Engine MRO, Spare Parts
EPS (Earnings per Share)
Revenue
Dividends
| Dividend Yield | 0.62% |
| Yield on Cost 5y | 1.08% |
| Yield CAGR 5y | -12.68% |
| Payout Consistency | 94.0% |
| Payout Ratio | 12.4% |
| Risk via 5d forecast | |
|---|---|
| Volatility | 25.1% |
| Value at Risk 5%th | 39.1% |
| Relative Tail Risk | -5.34% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.35 |
| Alpha | 2.97 |
| CAGR/Max DD | 0.54 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.609 |
| Beta | 0.271 |
| Beta Downside | 0.539 |
| Drawdowns 3y | |
|---|---|
| Max DD | 33.13% |
| Mean DD | 7.32% |
| Median DD | 4.50% |
Description: MTX MTU Aero Engines December 19, 2025
MTU Aero Engines AG (XETRA:MTX) designs, produces, markets, and services both commercial and military aircraft engines as well as aero-derivative gas turbines. Its operations are split between an Original Equipment Manufacturing (OEM) segment and a Maintenance, Repair & Overhaul (MRO) segment, covering a product range that spans wide-body, narrow-body, regional and business-jet engines, fighter-jet and helicopter powerplants, and industrial turbines.
Key recent metrics: FY 2023 revenue reached €13.2 bn, with an adjusted EBIT margin of roughly 9 %, reflecting strong demand in the commercial OEM market and a resilient MRO backlog of €7.5 bn. The company’s exposure to the CFM LEAP engine program-jointly owned with Safran-drives a significant portion of its order intake, while rising defense budgets in Europe and the U.S. underpin its military-engine segment. Fuel-price volatility and the pace of airline capacity restoration remain material macro-drivers of earnings.
For a deeper quantitative view of MTX’s valuation and risk profile, consider reviewing the data available on ValueRay.
Piotroski VR‑10 (Strict, 0-10) 6.5
| Net Income (1.35b TTM) > 0 and > 6% of Revenue (6% = 732.1m TTM) |
| FCFTA 0.03 (>2.0%) and ΔFCFTA -1.69pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 15.69% (prev 12.01%; Δ 3.68pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.07 (>3.0%) and CFO 778.0m <= Net Income 1.35b (YES >=105%, WARN >=100%) |
| Net Debt (1.18b) to EBITDA (2.09b) ratio: 0.56 <= 3.0 (WARN <= 3.5) |
| Current Ratio 1.39 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (54.3m) change vs 12m ago -3.94% (target <= -2.0% for YES) |
| Gross Margin 19.06% (prev -3.93%; Δ 22.99pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 107.3% (prev 71.82%; Δ 35.51pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 14.0 (EBITDA TTM 2.09b / Interest Expense TTM 119.0m) >= 6 (WARN >= 3) |
Altman Z'' 3.48
| (A) 0.16 = (Total Current Assets 6.79b - Total Current Liabilities 4.88b) / Total Assets 11.78b |
| (B) 0.28 = Retained Earnings (Balance) 3.32b / Total Assets 11.78b |
| (C) 0.15 = EBIT TTM 1.67b / Avg Total Assets 11.37b |
| (D) 0.49 = Book Value of Equity 3.85b / Total Liabilities 7.87b |
| Total Rating: 3.48 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 80.23
| 1. Piotroski 6.50pt |
| 2. FCF Yield 1.70% |
| 3. FCF Margin 2.82% |
| 4. Debt/Equity 0.64 |
| 5. Debt/Ebitda 0.56 |
| 6. ROIC - WACC (= 14.65)% |
| 7. RoE 37.87% |
| 8. Rev. Trend 44.24% |
| 9. EPS Trend 85.76% |
What is the price of MTX shares?
Over the past week, the price has changed by -0.42%, over one month by +0.40%, over three months by -5.38% and over the past year by +10.59%.
Is MTX a buy, sell or hold?
What are the forecasts/targets for the MTX price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 413.5 | 16.9% |
| Analysts Target Price | - | - |
| ValueRay Target Price | 383.7 | 8.5% |
MTX Fundamental Data Overview December 29, 2025
Market Cap EUR = 19.02b (19.02b EUR * 1.0 EUR.EUR)
P/E Trailing = 22.8341
P/E Forward = 19.8413
P/S = 2.2503
P/B = 4.9503
P/EG = 1.2723
Beta = 0.967
Revenue TTM = 12.20b EUR
EBIT TTM = 1.67b EUR
EBITDA TTM = 2.09b EUR
Long Term Debt = 1.97b EUR (from longTermDebt, last quarter)
Short Term Debt = 288.0m EUR (from shortTermDebt, last quarter)
Debt = 2.45b EUR (from shortLongTermDebtTotal, last quarter)
Net Debt = 1.18b EUR (from netDebt column, last quarter)
Enterprise Value = 20.20b EUR (19.02b + Debt 2.45b - CCE 1.27b)
Interest Coverage Ratio = 14.0 (Ebit TTM 1.67b / Interest Expense TTM 119.0m)
FCF Yield = 1.70% (FCF TTM 344.0m / Enterprise Value 20.20b)
FCF Margin = 2.82% (FCF TTM 344.0m / Revenue TTM 12.20b)
Net Margin = 11.06% (Net Income TTM 1.35b / Revenue TTM 12.20b)
Gross Margin = 19.06% ((Revenue TTM 12.20b - Cost of Revenue TTM 9.88b) / Revenue TTM)
Gross Margin QoQ = 22.39% (prev 17.53%)
Tobins Q-Ratio = 1.71 (Enterprise Value 20.20b / Total Assets 11.78b)
Interest Expense / Debt = 3.35% (Interest Expense 82.0m / Debt 2.45b)
Taxrate = 29.41% (240.0m / 816.0m)
NOPAT = 1.18b (EBIT 1.67b * (1 - 29.41%))
Current Ratio = 1.39 (Total Current Assets 6.79b / Total Current Liabilities 4.88b)
Debt / Equity = 0.64 (Debt 2.45b / totalStockholderEquity, last quarter 3.84b)
Debt / EBITDA = 0.56 (Net Debt 1.18b / EBITDA 2.09b)
Debt / FCF = 3.42 (Net Debt 1.18b / FCF TTM 344.0m)
Total Stockholder Equity = 3.56b (last 4 quarters mean from totalStockholderEquity)
RoA = 11.45% (Net Income 1.35b / Total Assets 11.78b)
RoE = 37.87% (Net Income TTM 1.35b / Total Stockholder Equity 3.56b)
RoCE = 30.11% (EBIT 1.67b / Capital Employed (Equity 3.56b + L.T.Debt 1.97b))
RoIC = 21.13% (NOPAT 1.18b / Invested Capital 5.56b)
WACC = 6.48% (E(19.02b)/V(21.47b) * Re(7.01%) + D(2.45b)/V(21.47b) * Rd(3.35%) * (1-Tc(0.29)))
Discount Rate = 7.01% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 8.05%
Shares Correlation 3-Years: 33.33 | Cagr: 0.53%
[DCF Debug] Terminal Value 79.45% ; FCFE base≈408.4m ; Y1≈443.8m ; Y5≈556.0m
Fair Price DCF = 180.2 (DCF Value 9.69b / Shares Outstanding 53.8m; 5y FCF grow 9.84% → 3.0% )
EPS Correlation: 85.76 | EPS CAGR: 65.78% | SUE: 0.29 | # QB: 0
Revenue Correlation: 44.24 | Revenue CAGR: 46.21% | SUE: 2.32 | # QB: 1
EPS next Year (2026-12-31): EPS=18.88 | Chg30d=+0.046 | Revisions Net=+2 | Growth EPS=+5.9% | Growth Revenue=+9.3%